Definium Therapeutics: Advancing Late-Stage Psychedelic Pipeline and Diversifying Assets Underpin Buy Rating and $61 Target

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Definium Therapeutics. The associated price target remains the same with $61.00.

Justin Walsh has given his Buy rating due to a combination of factors tied to Definium Therapeutics’ advancing clinical pipeline and upcoming catalysts. He highlights 2026 as a pivotal year, with three Phase III trials of the company’s lead compound, DT120, expected to deliver late-stage data across multiple psychiatric indications. Positive outcomes from these studies could support regulatory filings and position DT120 as a key player within the evolving interventional psychiatry landscape. Walsh also notes that the broader psychedelics market in neuropsychiatry is unlikely to be dominated by a single winner, suggesting room for several successful products and, by extension, meaningful commercial opportunity for Definium.
In addition, Walsh points to the company’s efforts to diversify beyond DT120, particularly through the advancement of DT402, its R-MDMA–based candidate for autism spectrum disorder now in Phase IIa testing. Initial results from this program, expected in the near term, may provide further validation of Definium’s platform and broaden its clinical reach. Combined with a solid cash position to fund development and planned investor communications such as the 2Q26 Analyst Day, these factors support his conviction that Definium is well positioned both clinically and financially, justifying a Buy rating and a $61 price target.

Walsh covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Perspective Therapeutics, and Actinium Pharmaceuticals. According to TipRanks, Walsh has an average return of 16.6% and a 36.45% success rate on recommended stocks.

In another report released on January 15, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $17.00 price target.